Last reviewed · How we verify
Gocovri (AMANTADINE)
Gocovri (amantadine) is a small molecule modality developed by Endo Pharms, targeting the Sigma non-opioid intracellular receptor 1. Originally approved in 1968, it is an influenza A M2 protein inhibitor with a 90% bioavailability and a half-life of 16 hours. Gocovri is used to treat various conditions, including Parkinson's disease, Parkinsonism, and influenza A, and is available as a generic medication due to its off-patent status. With over 30 generic manufacturers, Gocovri is widely accessible. As an off-patent medication, its commercial status is generic.
At a glance
| Generic name | AMANTADINE |
|---|---|
| Sponsor | Endo |
| Drug class | Influenza A M2 Protein Inhibitor |
| Target | Sigma non-opioid intracellular receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1968 |
Approved indications
- Arteriosclerotic Parkinsonism
- Extrapyramidal disease
- Influenza A Prevention
- Influenza due to Influenza A virus
- Parkinson's disease
- Parkinsonism
- Postencephalitic parkinsonism
Common side effects
- Nausea
- Dizziness/lightheadedness
- Insomnia
- Depression
- Congestive heart failure
- Convulsion
- Anxiety and irritability
- Psychosis
- Leukopenia
- Hallucinations
- Urinary retention
- Neutropenia
Drug interactions
- bupropion
Key clinical trials
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
- Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (PHASE2,PHASE3)
- Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) (EARLY_PHASE1)
- Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions (PHASE3)
- Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gocovri CI brief — competitive landscape report
- Gocovri updates RSS · CI watch RSS
- Endo portfolio CI